Scholarlink

<p>Molluscum contagiosum (MC) is a viral skin infection caused by a DNA virus from the Poxviridae family, typically presenting as pink, umbilicated papules or nodules. While commonly seen in children, MC in adults is often sexually transmitted. Immunosuppressed individuals, including those receiving biological therapies, are at greater risk for extensive and treatment-resistant lesions. Fingolimod, an immunomodulatory agent used in multiple sclerosis (MS), inhibits lymphocyte egress from lymph nodes, reducing T-cell-mediated immune responses and increasing susceptibility to infections, including MC. We report the case of a 35-year-old male with MS, treated with fingolimod for 5 years, who developed extensive genital lesions consistent with MC. Dermatological examination confirmed the diagnosis through clinical findings, Tzanck smear, and histopathology. Despite initial cryotherapy, the lesions persisted. A therapeutic approach using daily topical 10% potassium hydroxide solution was effective, leading to significant lesion regression within 1 month, allowing continuation of fingolimod therapy without interruption. A review of the literature identified 16 reported cases of MC associated with fingolimod therapy. These cases predominantly involved genital lesions and occurred in patients with significantly reduced lymphocyte counts. Therapeutic outcomes varied, with chemical treatments such as potassium hydroxide proving effective in cases unresponsive to physical interventions like cryotherapy or curettage.This case underscores the importance of recognizing MC as a potential complication in fingolimod-treated patients and highlights the utility of potassium hydroxide as a non-invasive treatment option. For patients unresponsive to treatment, collaboration with neurology teams is crucial to evaluate the potential need for altering immunosuppressive therapy. Dermatologists and neurologists should remain vigilant for MC in this population to ensure prompt diagnosis and effective management. This case highlights molluscum contagiosum as a potential complication of fingolimod therapy in multiple sclerosis patients. Topical potassium hydroxide proved effective for treatment, allowing continued immunotherapy. A multidisciplinary approach is essential for managing refractory cases while ensuring optimal MS treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molluscum Contagiosum in an Adult with Multiple Sclerosis on Fingolimod: A Case Report and Literature Review

  • 期刊论文

  • 发表日期：

    2025年4月4日

查看全文
  • Ahmet Kayaalti,
  • Serife Gamze Gemicioglu,
  • Ilknur Kivanc Altunay,
  • Asli Aksu,
  • Birgul Ozkesici Kurt

摘要

Molluscum contagiosum (MC) is a viral skin infection caused by a DNA virus from the Poxviridae family, typically presenting as pink, umbilicated papules or nodules. While commonly seen in children, MC in adults is often sexually transmitted. Immunosuppressed individuals, including those receiving biological therapies, are at greater risk for extensive and treatment-resistant lesions. Fingolimod, an immunomodulatory agent used in multiple sclerosis (MS), inhibits lymphocyte egress from lymph nodes, reducing T-cell-mediated immune responses and increasing susceptibility to infections, including MC. We report the case of a 35-year-old male with MS, treated with fingolimod for 5 years, who developed extensive genital lesions consistent with MC. Dermatological examination confirmed the diagnosis through clinical findings, Tzanck smear, and histopathology. Despite initial cryotherapy, the lesions persisted. A therapeutic approach using daily topical 10% potassium hydroxide solution was effective, leading to significant lesion regression within 1 month, allowing continuation of fingolimod therapy without interruption. A review of the literature identified 16 reported cases of MC associated with fingolimod therapy. These cases predominantly involved genital lesions and occurred in patients with significantly reduced lymphocyte counts. Therapeutic outcomes varied, with chemical treatments such as potassium hydroxide proving effective in cases unresponsive to physical interventions like cryotherapy or curettage.This case underscores the importance of recognizing MC as a potential complication in fingolimod-treated patients and highlights the utility of potassium hydroxide as a non-invasive treatment option. For patients unresponsive to treatment, collaboration with neurology teams is crucial to evaluate the potential need for altering immunosuppressive therapy. Dermatologists and neurologists should remain vigilant for MC in this population to ensure prompt diagnosis and effective management. This case highlights molluscum contagiosum as a potential complication of fingolimod therapy in multiple sclerosis patients. Topical potassium hydroxide proved effective for treatment, allowing continued immunotherapy. A multidisciplinary approach is essential for managing refractory cases while ensuring optimal MS treatment.